Evidence map›Paper›PMID 8991014›Full record

ArticleBMJ (Clinical research ed.)

Product names, proper claims? More ethical issues in the marketing of drugs.

S Holm, M Evans

Abstract read
In one paragraph

Article in BMJ (Clinical research ed.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The power of placebo.BMJ (Clinical research ed.)
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

S HolmDepartment of Medical Philosophy and Clinical Theory, University of Copenhagen, Denmark.
M Evans

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo analyse the explicit or implicit claims embodied in the proprietary names of pharmaceutical products.

designLinguistic and ethical analysis of proprietary names of pharmaceutical products marketed in the UK and in Denmark. RESULTS AND

conclusionsA number of drugs have names that allude to their indication or actions. Such names may be problematic, however, because they often promise more than the drug can deliver. Taking into account, firstly, the type of allusion and its degree of sophistication, and, secondly, the seriousness of the indication may help in identifying the most problematic drug names.

Indexed as

EthicsEthics, BusinessEthics, MedicalPharmaceutical PreparationsTerminology as TopicDenmarkDrug IndustryRisk AssessmentUnited KingdomPharmaceutical PreparationsEmpirical ApproachProfessional Patient Relationship

Identifiers

PMID8991014
PMCPMC2359129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.